Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 12, 2005, Pages 1486-1492

  Sezgin, Canfeza ^a   Karabulut, Bulent ^a   Uslu, Ruchan ^a   Sanli, Ulus A ^a   Goksel, Gamze ^c   Yuzer, Yildiray ^b   Goker, Erdem ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Tulay Aktas Oncology Hospital   (Turkey)

^c CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Gemcitabine; Pancreatic carcinoma; Prognostic factors; Survival

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NEUTROPENIA; PANCREAS CARCINOMA; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TUMOR LOCALIZATION; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 29744469471     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520510023819     Document Type: Article

References (24)

1. Cascinu S, Graziano F, Catalano G. Chemotherapy for advanced pancreatic cancer: it may no longer be ignored. Ann Oncol 1999;10:105-9.
2. Hertel LW, Kroin JS, Misner JW, Tustin JM. Synthesis of 2-deoxy-2′,2′difluoro-D-ribose and 2-deoxy-2′, 2′difluoro-D-ribose and 2-deoxy-2′,2′difluoro-D-fibofuranosyl nucleosides. J Organ Chem 1988;53:2406.
3. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
4. Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 2002;20:665-73.
5. McKenna S, Eatock M. The medical management of pancreatic cancer: a review. Oncologist 2003;8:149-60.
6. Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 1996;12:267-71.
7. Fujino Y, Suzuki Y, Ajiki T, Tanioka Y, Ku Y, Kuroda Y. Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline. Hepatogastroenterology 2003;50:250-1.
8. Terwee CB, Nieveen Van Dijkum EJ, Gouma DJ, Bakkevold KE, Klinkenbijl JH, Wade TP, et al. Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: the Triple-P study. Triple-P study group. Eur J Surg 2000;166:706-12.
9. Cubiella J, Castells A, Fondevilla C, Sans M, Sabater L, Navarro S, et al. Prognostics factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterol 1999;94:1271-8.
10. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000;59:296-301.
11. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic cancer carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-5.
12. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302.
13. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7.
14. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8.
15. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 2001;24:547-50.
16. Engelken FJ, Bettschart V, Rahman MQ, Parks RW, Garden OJ. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 2003;29:368-73.
17. Talar-Wojnarowska R, Gasiorowska A, Strzelczyk J, Janiak A, Malecka-Panas E. Prognostic factors in the operative and palliative treatment of pancreatic cancer. Neoplazma 2003;50:383-7.
18. Kamisawa T, Yuyang T, Egawa N, Ishiwata J, Tsuruta K, Okamoto A, et al. Characteristics of pancreatic carcinoma in elderly. Int J Pancreatol 1998;24:31-4.
19. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999;17:3631-57.
20. Li D, Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 2003;33:3-14.
21. Ganti AK, Potti A, Koch M, Tendulkar K, Hanekom D, Koka V, et al. Predictive value of clinical features at initial presentation in pancreatic adenocarcinoma: a series of 308 cases. Med Oncol 2002;19:233-7.
22. Yu GP, Ostroff JS, Zhang ZF, Tang J, Schantz SP. Smoking history and cancer patient survival: a hospital cancer registry study. Cancer Detect Prev 1997;21:497-509.
23. Saruc M, Pour PM. Diabetes and its relationship to pancreatic carcinoma. Pancreas 2003;26:381-7.
24. Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol 2001;6:50-4.